Wuhan Vanz Pharm Inc.

 

Wuhan Vanz Pharm Inc., Your reliable supplier!

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsActive Pharmaceutical Ingredient

Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7

Good quality Pharmaceutical Intermediates for sales
Good quality Pharmaceutical Intermediates for sales
I am very happy to cooperate with your company for nearly three years, thank you very attentive service, thank you for the excellent product quality.

—— Stephnie

You always have very fast delivery, very happy to cooperate with you. Thank you.

—— John

Very pleased to become your customer, and very happy for our cooperation, hope to be your long-term parter.

—— Sara

we received the package, very fast, the quality is very good, will continue to buy your products.

—— Luice

I have emailed you a couple times and they get returned as undeliverable. Yes. I am happy with the powders. thank you.

—— Bryan

I'm Online Chat Now

Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7

China Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7  supplier
Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7  supplier Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7  supplier

Large Image :  Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7

Product Details:

Place of Origin: China
Brand Name: vanz
Certification: ISO9001
Model Number: 2022-85-7

Payment & Shipping Terms:

Minimum Order Quantity: 1kg
Packaging Details: bags or drum
Delivery Time: 3-5 days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 200kg per month
Contact Now
Detailed Product Description
Name: Flucytosine CAS: 2022-85-7
Appearance: White Powder COA: Available
Assay: 99%min Stock: Available

Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7

 

Introduction

 

Flucytosine, or 5-fluorocytosine, a fluorinated pyrimidine analogue, is a synthetic antimycotic drug.

It is structurally related to the cytostatic fluorouracil and to floxuridine. It is available in oral and in some countries also in injectable form. A common brand name is Ancobon. Flucytosine was first synthesized in 1957 but its antifungal properties were discovered in 1964. The drug is dispensed in capsules of 250 mg and 500 mg strength. The injectable form is diluted in 250 mL saline solution to contain 2.5 g total (10 mg/mL). The solution is physically incompatible with other drugs including amphotericin B.

It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system.

 

Product Name Fluorocytosine
Synonyms

2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 5-Fluorocytosine;

Alcobon; Ancobon; Ancotil

CAS NO. 2022-85-7
EINECS 217-968-7
Molecular Formula C4H4FN3O
Molecular Weight 129.09
Specifications:
Standard Assay ≥99%
Appearance White crystalline powder
Melting Point 296℃
Other information:
Packing 100G;500G;1Kg;25Kg(Export worthy packing)
Applications Used as Capecitabine intermediate
Status Commercials
Remark For more details,please contact us

 

Side Effects

  1. Patients treated with drugs compromising bone marrow function (e.g. cytostatics) should be treated carefully. Blood cell counts should be taken very frequently.
  2. Patients with renal disease should receive flucytosine cautiously and in reduced doses. Guidelines for proper dosing exist. Serum level determinations are mandatory for these patients.
  3. All patients receiving flucytosine should be under strict medical supervision.
  4. Hematological, renal and liver function studies should be done frequently during therapy (initially daily, twice a week for the rest of treatment).
  5. Patients with preexisting bone marrow depression and liver impairment should be treated with caution.
  6. Antiproliferative actions on bone marrow and GI tissue: Due to the drug's preference for rapidly proliferating tissues, bone marrow depression (anemia, leukopenia, pancytopenia, or even rarely agranulocytosis) may occur. Aplastic anemia has also been seen. Bone marrow toxicity can be irreversible and may cause death, particularly in immunocompromised patients. GI toxicity may be severe or rarely fatal and consists of anorexia, abdominal bloating, abdominal pain, diarrhea, dry mouth, duodenal ulcer, GI hemorrhage, nausea, vomiting, and ulcerative colitis.
  7. Liver function: Elevations of liver enzymes and bilirubin, hepatic dysfunction, jaundice and, in one patient, liver necrosis have all been seen. Some fatal cases have been reported; however, the majority of cases was reversible.
  8. Renal function: Increased BUN and serum creatinine have been noted. Crystalluria (formation of crystals and excretion in the urine) and acute renal failure have also been seen.
  9. Adverse central nervous system effects are frequent and include confusion, hallucinations, psychosis, ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, vertigo and sedation.
  10. Skin reactions: Rash, pruritus, and photosensitivity have all been noticed. Toxic epidermal necrolysis (Lyell's syndrome) may also be encountered and may be life-threatening.
  11. Anaphylaxis: Sometimes cases of anaphylaxis consisting of diffuse erythema, pruritus, conjunctival injection, fever, abdominal pain, edema, hypotension and bronchospastic reactions are observed.
  12. It is not known if flucytosine is a human carcinogen. The issue has been raised because traces of 5-fluorouracil, which is a known carcinogen, are found in the colon resulting from the metabolization of flucytosine.

Flucytosine 5-Fluorocytosine Api Intermediates Antimycotic Drug CAS 2022-85-7

Contact Details
Wuhan Vanz Pharm Inc.

Contact Person: Amy

Tel: +8613277095342

Send your inquiry directly to us (0 / 3000)